Brought to you by 
Cortical and Genzyme in inflammatory disease alliance
02 Feb 2004
Executive Summary
Genzyme and Australian drug discovery company Cortical have entered into an agreement to develop oral drugs for inflammatory diseases based on the inhibition of the macrophage inhibitory factor (MIF).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cortical and Genzyme in inflammatory disease alliance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice